Background: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatment due to unknown symptom onset time and limited availability of advanced imaging modalities. The Tenecteplase in Wake-up lschaemic Stroke Trial (TWIST) is a randomized controlled trial of intravenous tenecteplase 0.25 mg/kg and standard care versus standard care alone (no thrombolysis) in patients who wake up with acute ischemic stroke and can be treated within 4.5 h of wakening based on non-contrast CT findings. Objective: To publish the detailed statistical analysis plan for TWIST prior to unblinding. Methods: The TWIST statistical analysis plan is consistent with the Consolidating Standard of Reporting Trials (CON-SORT) statement and provi...
Rationale: In about 20% of acute ischemic stroke patients stroke occurs during sleep. These patient...
Background: Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenectep...
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasmi...
Background: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatmen...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advanced...
RATIONALE: Thrombolysis with intravenous alteplase is both effective and safe when administered to p...
RationaleEndovascular treatment has been shown to restore blood flow effectively. Second-generation ...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients...
Endovascular treatment has been shown to restore blood flow effectively. Second-generation medical d...
Rationale: Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reduci...
Background: Cooling may reduce infarct size and improve neurological outcomes in patients with ischa...
Rationale: In about 20% of acute ischemic stroke patients stroke occurs during sleep. These patient...
Background: Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenectep...
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasmi...
Background: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatmen...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advanced...
RATIONALE: Thrombolysis with intravenous alteplase is both effective and safe when administered to p...
RationaleEndovascular treatment has been shown to restore blood flow effectively. Second-generation ...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients...
Endovascular treatment has been shown to restore blood flow effectively. Second-generation medical d...
Rationale: Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reduci...
Background: Cooling may reduce infarct size and improve neurological outcomes in patients with ischa...
Rationale: In about 20% of acute ischemic stroke patients stroke occurs during sleep. These patient...
Background: Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenectep...
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasmi...